1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

27 Dec 2021
Admin
News Article

Novartis To Test Novel Launch Strategy For Cholesterol Drug Leqvio

To Avoid The Fate Of Pcsk9 Inhibitors Repatha (Evocolumab) And Praluent (Alirocumab), Which Have Muddled Through Underwhelming Launches In Recent Years, Novartis Pharmaceuticals President Marie-France Tschudin Said The Company Plans To Work Directly With The Top 200 Hospital Systems In The Us To Identify Patients Who Would Be Most Likely To Benefit From Leqvio (Inclisiran). Time Will Tell Whether Its Launch Strategy Will Translate Into Improved Uptake Versus The Pcsk9 Drugs That Came Before It. What HappenedThe Fda Approved Leqvio, A Pcsk9-Targeting Sirna Therapy, To Lower Ldl Cholesterol. Leqvio Is Administered Twice Per Year After Two Initial Doses Within The First Three Months Of Treatment. Novartis Plans To Launch The Drug In Early January 2022 At $3,250 Per Dose, Which Would Be $9,750 The First Year And $6,500 In Subsequent Years. The BackstoryWhile The Fda Issued A Complete Response Letter For Leqvio In December 2020, Citing An Inspection Issue At A Third-Party Manufacturing Facility, Analysts And Physicians Largely Believe The Molecule Could Change The Way High Cholesterol Is Treated Given The Convenience Of Its Twice-Yearly Dosing Profile. Many Analysts Think Novartis Overpaid To Acquire Leqvio

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!